お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、グルカゴン様ペプチド-1（GLP-1）アゴニストの世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別にグルカゴン様ペプチド-1（GLP-1）アゴニスト市場を分類しています。
本レポートでは世界のグルカゴン様ペプチド-1（GLP-1）アゴニスト市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Novo Nordisk、AstraZeneca、Eli Lily、GSK、Sanofi、Bristol-Myers Squibb、Amylin

レポートはグルカゴン様ペプチド-1（GLP-1）アゴニストの主要生産者を調査し、主要地域や国の消費状況も提供します。グルカゴン様ペプチド-1（GLP-1）アゴニストの今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Exenatied
    Liraglutide
    Lixisenatide
    Albiglutide
    Dulaglutide

用途別の市場セグメント：
    Hospital
    Pharmacy
    Other

本レポートの詳細内容
本レポートは、世界のグルカゴン様ペプチド-1（GLP-1）アゴニスト市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてグルカゴン様ペプチド-1（GLP-1）アゴニスト市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別（地域レベル、国レベル）のグルカゴン様ペプチド-1（GLP-1）アゴニスト生産量、成長率、市場シェアを調査している。

二. 消費面では、グルカゴン様ペプチド-1（GLP-1）アゴニストの売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。

三.主要メーカーのグルカゴン様ペプチド-1（GLP-1）アゴニスト売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のグルカゴン様ペプチド-1（GLP-1）アゴニスト市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本グルカゴン様ペプチド-1（GLP-1）アゴニストのレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：グルカゴン様ペプチド-1（GLP-1）アゴニストのレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2019～2030）
第2章： グルカゴン様ペプチド-1（GLP-1）アゴニストの世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2019～2030）
第3章：世界、地域、国レベルにおけるグルカゴン様ペプチド-1（GLP-1）アゴニストの売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2019～2030）
第4章グルカゴン様ペプチド-1（GLP-1）アゴニストメーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2019～2024）
第5章：グルカゴン様ペプチド-1（GLP-1）アゴニストの各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2019～2030）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2019～2030）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2019～2030）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第12章：グルカゴン様ペプチド-1（GLP-1）アゴニストの主要メーカーの概要を提供し、製品の説明と仕様、グルカゴン様ペプチド-1（GLP-1）アゴニストの売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2019～2024）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：グルカゴン様ペプチド-1（GLP-1）アゴニストの市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is projected to grow from US$ 10090 million in 2024 to US$ 21340 million by 2030, at a Compound Annual Growth Rate (CAGR) of 13.3% during the forecast period.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.
Report Covers:
This report presents an overview of global market for Glucagon Like Peptide-1 (GLP-1) Agonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Glucagon Like Peptide-1 (GLP-1) Agonists, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Glucagon Like Peptide-1 (GLP-1) Agonists, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Glucagon Like Peptide-1 (GLP-1) Agonists sales, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
    Novo Nordisk
    AstraZeneca
    Eli Lily
    GSK
    Sanofi
    Bristol-Myers Squibb
    Amylin

Segment by Type
    Exenatied
    Liraglutide
    Lixisenatide
    Albiglutide
    Dulaglutide

Segment by Application
    Hospital
    Pharmacy
    Other

Segment by Region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
    Table 1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Table 2. Major Manufacturers of Exenatied
    Table 3. Major Manufacturers of Liraglutide
    Table 4. Major Manufacturers of Lixisenatide
    Table 5. Major Manufacturers of Albiglutide
    Table 6. Major Manufacturers of Dulaglutide
    Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2019-2024) & (US$ Million)
    Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2025-2030) & (US$ Million)
    Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2019-2024)
    Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2025-2030)
    Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2024) & (K Units)
    Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2025-2030) & (K Units)
    Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2019-2024)
    Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2025-2030)
    Table 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers (2019-2024) & (K Units)
    Table 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturers (2019-2024)
    Table 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2019-2024) & (US$ Million)
    Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers (2019-2024)
    Table 22. Global Key Players of Glucagon Like Peptide-1 (GLP-1) Agonists, Industry Ranking, 2022 VS 2023 VS 2024
    Table 23. Glucagon Like Peptide-1 (GLP-1) Agonists Price by Manufacturers 2019-2024 (USD/Unit)
    Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2023)
    Table 26. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Base Distribution and Headquarters
    Table 27. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Offered and Application
    Table 28. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Date of Enter into This Industry
    Table 29. Mergers & Acquisitions, Expansion Plans
    Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
    Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
    Table 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2019-2024)
    Table 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2025-2030)
    Table 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
    Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
    Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2019-2024)
    Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2025-2030)
    Table 38. Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2019-2024) & (USD/Unit)
    Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Type (2025-2030) & (USD/Unit)
    Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
    Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
    Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2019-2024)
    Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2025-2030)
    Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
    Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
    Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2019-2024)
    Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2025-2030)
    Table 48. Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2019-2024) & (USD/Unit)
    Table 49. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Application (2025-2030) & (USD/Unit)
    Table 50. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
    Table 51. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
    Table 52. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
    Table 53. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
    Table 54. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
    Table 55. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
    Table 56. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
    Table 57. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
    Table 58. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 59. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2024) & (US$ Million)
    Table 60. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2025-2030) & (US$ Million)
    Table 61. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024) & (K Units)
    Table 62. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030) & (K Units)
    Table 63. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
    Table 64. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
    Table 65. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
    Table 66. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
    Table 67. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
    Table 68. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
    Table 69. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
    Table 70. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
    Table 71. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 72. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2024) & (US$ Million)
    Table 73. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2025-2030) & (US$ Million)
    Table 74. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024) & (K Units)
    Table 75. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030) & (K Units)
    Table 76. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
    Table 77. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
    Table 78. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
    Table 79. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
    Table 80. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
    Table 81. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
    Table 82. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
    Table 83. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
    Table 84. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
    Table 85. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
    Table 86. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
    Table 87. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
    Table 88. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
    Table 89. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
    Table 90. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
    Table 91. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
    Table 92. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 93. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2019-2024) & (US$ Million)
    Table 94. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2025-2030) & (US$ Million)
    Table 95. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2024) & (K Units)
    Table 96. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2025-2030) & (K Units)
    Table 97. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
    Table 98. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
    Table 99. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
    Table 100. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
    Table 101. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
    Table 102. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
    Table 103. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
    Table 104. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
    Table 105. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 106. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2024) & (US$ Million)
    Table 107. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2025-2030) & (US$ Million)
    Table 108. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024) & (K Units)
    Table 109. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030) & (K Units)
    Table 110. Novo Nordisk Company Information
    Table 111. Novo Nordisk Description and Major Businesses
    Table 112. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 113. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. Novo Nordisk Recent Developments
    Table 115. AstraZeneca Company Information
    Table 116. AstraZeneca Description and Major Businesses
    Table 117. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 118. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
    Table 119. AstraZeneca Recent Developments
    Table 120. Eli Lily Company Information
    Table 121. Eli Lily Description and Major Businesses
    Table 122. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 123. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
    Table 124. Eli Lily Recent Developments
    Table 125. GSK Company Information
    Table 126. GSK Description and Major Businesses
    Table 127. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 128. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
    Table 129. GSK Recent Developments
    Table 130. Sanofi Company Information
    Table 131. Sanofi Description and Major Businesses
    Table 132. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 133. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
    Table 134. Sanofi Recent Developments
    Table 135. Bristol-Myers Squibb Company Information
    Table 136. Bristol-Myers Squibb Description and Major Businesses
    Table 137. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 138. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
    Table 139. Bristol-Myers Squibb Recent Developments
    Table 140. Amylin Company Information
    Table 141. Amylin Description and Major Businesses
    Table 142. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 143. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
    Table 144. Amylin Recent Developments
    Table 145. Key Raw Materials Lists
    Table 146. Raw Materials Key Suppliers Lists
    Table 147. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
    Table 148. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List
    Table 149. Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends
    Table 150. Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
    Table 151. Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
    Table 152. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
    Table 153. Research Programs/Design for This Report
    Table 154. Key Data Information from Secondary Sources
    Table 155. Key Data Information from Primary Sources
List of Figures
    Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture
    Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Type in 2023 & 2030
    Figure 4. Exenatied Product Picture
    Figure 5. Liraglutide Product Picture
    Figure 6. Lixisenatide Product Picture
    Figure 7. Albiglutide Product Picture
    Figure 8. Dulaglutide Product Picture
    Figure 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Application in 2023 & 2030
    Figure 11. Hospital
    Figure 12. Pharmacy
    Figure 13. Other
    Figure 14. Glucagon Like Peptide-1 (GLP-1) Agonists Report Years Considered
    Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2019-2030 (US$ Million)
    Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region in Percentage: 2023 Versus 2030
    Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2019-2030)
    Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2019-2030 ((K Units)
    Figure 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2019-2030)
    Figure 21. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
    Figure 22. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
    Figure 23. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
    Figure 24. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
    Figure 25. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
    Figure 26. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
    Figure 27. Asia (excluding China) Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
    Figure 28. Asia (excluding China) Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
    Figure 29. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
    Figure 30. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
    Figure 31. The Glucagon Like Peptide-1 (GLP-1) Agonists Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
    Figure 32. The Top 5 and 10 Largest Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists in the World: Market Share by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2023
    Figure 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
    Figure 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
    Figure 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
    Figure 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
    Figure 38. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
    Figure 39. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
    Figure 40. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
    Figure 41. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
    Figure 42. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2019-2030)
    Figure 43. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2019-2030)
    Figure 44. U.S. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 45. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 46. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
    Figure 47. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
    Figure 48. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
    Figure 49. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
    Figure 50. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2019-2030)
    Figure 51. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2019-2030)
    Figure 52. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 53. France Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 54. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 55. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 56. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 57. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
    Figure 58. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
    Figure 59. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
    Figure 60. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
    Figure 61. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
    Figure 62. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
    Figure 63. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
    Figure 64. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
    Figure 65. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Region (2019-2030)
    Figure 66. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Region (2019-2030)
    Figure 67. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 68. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 69. China Taiwan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 70. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 71. India Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 72. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
    Figure 73. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
    Figure 74. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
    Figure 75. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
    Figure 76. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2019-2030)
    Figure 77. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2019-2030)
    Figure 78. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 79. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 80. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 81. Israel Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 82. GCC Countries Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
    Figure 83. Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain
    Figure 84. Glucagon Like Peptide-1 (GLP-1) Agonists Production Process
    Figure 85. Channels of Distribution
    Figure 86. Distributors Profiles
    Figure 87. Bottom-up and Top-down Approaches for This Report
    Figure 88. Data Triangulation
    Figure 89. Key Executives Interviewed